Kangstem Biotech Co (XKRX:217730) Net Income (Continuing Operations) : ₩-8,394 Mil (TTM As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Kangstem Biotech Co Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Kangstem Biotech Co's Net Income (Continuing Operations) for the three months ended in Mar. 2025 was ₩-4,903 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 was ₩-8,394 Mil.

Kangstem Biotech Co Net Income (Continuing Operations) Historical Data

The historical data trend for Kangstem Biotech Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kangstem Biotech Co Net Income (Continuing Operations) Chart

Kangstem Biotech Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income (Continuing Operations)

Get a 7-Day Free Trial

-19,745.80

-21,826.78

-20,176.26

-23,221.11

-7,082.86

Kangstem Biotech Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income (Continuing Operations)	Get a 7-Day Free Trial															-4,171.80	4,816.12	-4,030.46	-4,276.76	-4,903.06

Kangstem Biotech Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-8,394 Mil.

Kangstem Biotech Co (XKRX:217730) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Kangstem Biotech Co Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Kangstem Biotech Co's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Kangstem Biotech Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kangstem Biotech Co Ltd (XKRX:217730) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

N/A

Address

512 Teheran-ro, Gangnam-gu, 17th Floor, Sinan Building, Seoul, KOR

Website

http://www.kangstem.com

Kangstem Biotech Co Ltd develops technology to isolate the non-hematological system stem cell with conversion and purity from the cord blood and to culture large quantity. Its Furestem therapies include Furestem-AD, Furestem-RA and Furestem-CD. Its businesses include cord blood-derived stem cell therapy business; cord blood-derived stem cell conditioned media business; and stem cell culture media business.

Kangstem Biotech Co Headlines

No Headlines